Amid Growing Focus on Treatments for Metabolic and Liver Diseases, H.C. Wainwright Bullish on Altimmune (ALT)

Corroborated by 2 sources from 2 publishers

globalhealth1d ago

TL;DR

H.C. Wainwright reiterates Neutral rating on Phunware stock at $2 H.C. Wainwright reiterates Buy on Achieve Life Sciences stock Altimmune, Inc.

Sources